Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ensartinib in ALK-positive NSCLC After Second-generation ALK-TKI Resistance
NCT05178511Phase 2Unknown
- Start
- Dec 2021
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ensartinib in non-small cell lung cancer (NSCLC). Primary endpoint: Objective Response Rate up to 8 weeks. Status: unknown.
02
Drugs
ensartinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05178511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05178511.